10-K: Firefly Neuroscience Reports Soaring Revenue Amidst Going Concern Doubts

Firefly Neuroscience, Inc. reported a 957% revenue increase to $1.142 million in 2025, driven by the Evoke acquisition, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Summary

• Revenue for the year ended December 31, 2025, increased by 957% to $1.142 million, up from $108,000 in 2024, primarily due to the acquisition of Evoke Neuroscience.
• Net loss and comprehensive loss for 2025 was $(19.882) million, an increase from $(10.460) million in 2024.
• Operating expenses decreased by 6.5% to $9.501 million in 2025 from $10.162 million in 2024, mainly due to reduced research and development and selling and marketing expenses.
• General and administrative expenses increased by 13% to $6.968 million in 2025, largely due to D&O insurance costs post-Merger and accrued fees from an Equity Line of Credit cancellation.
• The company incurred a significant 'Change in derivative fair value' loss of $(9.369) million in 2025, compared to $(156,000) in 2024.
• Cash used in operating activities increased by 33% to $(8.194) million in 2025 from $(6.155) million in 2024.
• The acquisition of Evoke Neuroscience Inc. on April 30, 2025, for $6.221 million (consisting of $3.000 million cash and 857,142 common shares valued at $2.743 million, plus a $478,000 earn-out liability) significantly expanded business operations and headcount.
• As of December 31, 2025, the company had an accumulated deficit of $111.615 million and negative cash flows from operating activities of $8.194 million, raising substantial doubt about its ability to continue as a going concern.
• The company identified material weaknesses in internal control over financial reporting related to inadequate Information Technology General Controls (ITGC) and lack of segregation of duties.
• Subsequent to December 31, 2025, the company raised $150,000 from warrant exercises and $2.250 million from an initial private placement tranche, with an option for investors to purchase up to an additional $18.000 million.
• An At-the-Market (ATM) offering program was established on February 3, 2026, to sell up to $7.434 million in common stock.
• A warrant cancellation and exchange agreement on December 16, 2025, resulted in the exchange of 800,000 warrants (exercise prices $3.50 and $4.00) for new warrants at an exercise price of $0.50 per share, leading to a deemed dividend of $239,000.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to the significant net loss, substantial doubt about the company's ability to continue as a going concern, and identified material weaknesses in internal controls, despite notable revenue growth and recent capital raises.

Positives

• Revenue increased by 957% to $1.142 million in 2025, primarily driven by the Evoke Neuroscience acquisition.
• The Evoke System is in active use across more than 85 clinical sites in the United States as of December 31, 2025.
• The company's proprietary database includes over 191,000 standardized EEG and ERP assessment records, spanning over 12 distinct neurological and psychiatric disorders, representing a significant strategic asset.
• The Firefly Platform utilizes a subscription-based commercial model, creating a recurring revenue stream that scales with clinical utilization.
• The Evoke System has received FDA 510(k) clearance as a Class II medical device for EEG and ERP data acquisition, display, storage, and associated analytical/reporting functions.
• The company has a strong intellectual property portfolio with 23 issued U.S. patents as of December 31, 2025, with expiration dates ranging from November 2028 to November 2037.
• Research and development expenses decreased by 24% to $1.482 million in 2025, indicating some cost management in this area.
• The company successfully raised $150,000 from warrant exercises and $2.250 million from a private placement subsequent to year-end 2025, demonstrating continued access to capital.

Negatives

• The company incurred a net loss of $(19.882) million in 2025, an increase from $(10.460) million in 2024.
• An accumulated deficit of $111.615 million and negative cash flows from operating activities of $8.194 million as of December 31, 2025, raise substantial doubt about the company's ability to continue as a going concern.
• A significant loss of $(9.369) million was recorded due to the change in derivative fair value in 2025.
• A loss on settlement of promissory note of $(1.353) million was recognized in 2025.
• Material weaknesses in internal control over financial reporting were identified, specifically regarding Information Technology General Controls (ITGC) and lack of segregation of duties.
• The company made a strategic decision to discontinue the BNA software platform and Zeto headsets, resulting in an impairment loss of $251,000 in 2025.
• The warrant cancellation and exchange agreement on December 16, 2025, involved exchanging warrants with higher exercise prices ($3.50 and $4.00) for new warrants at a significantly lower exercise price ($0.50), leading to a deemed dividend of $239,000 and potential dilution.
• The company's market capitalization of approximately $12.3 million at December 31, 2025, was significantly lower than its peak, although it exceeded net assets.

Risks

• Significant liquidity risks raise substantial doubt about the company's ability to continue as a going concern, with no assurance of securing additional funding on favorable terms or at all.
• Strategic acquisitions, such as Evoke Neuroscience, involve risks including diversion of management attention, integration difficulties, failure to retain key personnel/customers, and potential legal liabilities.
• Issues with product development, IT system integration, cyber-attacks, or disruptions to third-party software/AI services could adversely affect operations and results.
• Failure to successfully initiate broad commercialization, market products cost-effectively, or achieve market acceptance could negatively impact sales and financial results.
• Intense competition in the medical device industry from well-capitalized companies with established sales and marketing programs could harm the company's competitive position.
• Patient and product variability may produce misleading report results, leading to customer dissatisfaction and harming sales.
• Inadequate training for clinicians using the platform could lead to negative experiences and limit adoption.
• High dependence on senior management and key personnel, with intense competition for skilled talent, poses a risk to business success.
• Inability to achieve or maintain satisfactory pricing and margins for products due to price competition or reduced third-party payor reimbursement.
• Ongoing changes in healthcare regulation, including those from the FDA and international bodies like the EU's Medical Devices Regulation, could increase compliance costs or restrict operations.
• Misuse or off-label promotion of products could harm reputation, lead to product liability suits, or result in costly investigations and sanctions.
• Exposure to federal, state, and foreign fraud and abuse laws, health information privacy and security laws (e.g., HIPAA, GDPR), and transparency laws, with potential for substantial penalties for violations.
• Restrictions on manufacturing and transfer of know-how outside of Israel due to Israeli Innovation Authority (IIA) grants, potentially impacting global operations or M&A.
• Difficulty enforcing U.S. judgments against the Israeli subsidiary or non-U.S. officers and directors.
• Cybersecurity incidents, including data breaches or computer viruses, could disrupt services, damage reputation, or expose the company to liability, especially with increased geopolitical conflict risks.
• Challenges with properly managing the use of AI in business, including flaws in algorithms, biased data, and evolving ethical/regulatory issues, could result in reputational harm, competitive harm, and legal liability.
• The company's 'baby shelf' status limits capital raising through Form S-3 to one-third of its public float, potentially constraining access to capital markets.
• The market price of common stock may be subject to significant fluctuations and volatility, and future sales or issuances of equity could result in substantial dilution to existing investors.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports or fraud, harming business and stock price.

Future Outlook

The company expects to continue incurring negative cash flows from operations for the next 12 months as it integrates products and expands its sales organization. Long-term profitability depends on the successful commercialization of its combined product portfolio, requiring substantial additional capital. Management is focused on disciplined operating expense management, realizing integration synergies from the Evoke acquisition, and targeted commercial expansion to drive recurring subscription revenue. The company is increasingly reliant on machine learning models, with performance depending on training data diversity and ongoing monitoring, subject to evolving regulatory guidance and payer expectations. The company also anticipates increased resources to enhance protective measures against cybersecurity threats.

Management Comments

• Management is primarily responsible for assessing, monitoring and managing our cybersecurity risks, ensuring all industry standard cybersecurity measures are functioning as required to prevent or detect cybersecurity threats and related risks.
• Management oversees and tests our compliance with standards, remediates known risks, and leads our employee training program.
• Management is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques, and implements processes for regular monitoring of information systems.
• In the event of a cybersecurity incident, management will implement an incident response plan, including immediate actions to mitigate impact and long-term strategies for remediation and prevention.
• Management has a reasonable expectation that we can continue raising additional capital to address the going concern issues.

Industry Context

StockSavvy.ai notes that Firefly Neuroscience operates in the rapidly evolving and competitive brain health diagnostics and precision neuroscience market. The company's strategy of combining FDA-cleared hardware (Evoke System) with AI-driven cloud-based analytics and a growing proprietary electrophysiological database positions it to address the unmet need for objective brain function measurement. The shift towards subscription-based models aligns with broader digital health trends, aiming for recurring revenue. The emphasis on early detection of cognitive decline and treatment selection support through biomarkers is a key differentiator in a market where conditions like MCI and early Alzheimer's are often detected late. The company's approach of integrating multimodal data (EEG, ERP, HRV) provides a richer physiological signal compared to single-modality tools, potentially offering a competitive edge against traditional EEG manufacturers and even structural neuroimaging modalities like MRI/CT by providing functional insights at a lower cost and greater accessibility in clinical settings. However, the industry faces challenges from rapidly advancing technology, intense competition, and complex regulatory landscapes, particularly concerning AI/ML-enabled medical devices and data privacy.

Comparison to Industry Standards

• The Evoke System's 19-channel EEG electrode array configured to the International 10-20 system is a clinical standard for electrode placement, aligning with established industry practices.
• The inclusion of a Heart Rate Variability (HRV) sensor for simultaneous autonomic nervous system measurement provides a multimodal data capture that distinguishes the hardware from more limited EEG-only assessment tools, potentially offering a competitive advantage over some industry offerings.
• The company's proprietary database of over 191,000 standardized EEG and ERP assessment records, spanning over 12 neuropsychiatric disorders and including healthy individuals, is a significant asset that may be difficult for smaller, less standardized datasets from competitors to replicate.
• The company's research collaborations and peer-reviewed publications (over 20) in indexed scientific journals, including studies on early Parkinson's detection (AUC of 0.79, sensitivity 0.74, specificity 0.73), MDD treatment monitoring, and ADHD endophenotyping, demonstrate a commitment to scientific validation comparable to leading research-driven medical technology firms.
• The FDA 510(k) clearance for the Evoke System as a Class II medical device is a standard regulatory pathway for commercial marketing in the U.S., indicating compliance with established medical device regulations.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• As of December 31, 2024, the company expensed $510,000 related to the Bower Four Strategic agreement due to a change in employment status for CEO Greg Lipschitz.
• Pursuant to the Lipschitz Agreement (August 12, 2024), Mr. Lipschitz, through Bower Four Corp., was entitled to receive aggregate consideration of $950,000 in Common Stock over three years for annual service credits. As of December 31, 2025, these service credits have been fully consumed.
• On June 7, 2024, Series D warrants to purchase 30,933 shares of common stock were granted to a company wholly owned by one of the company's directors, with a fair value of $203,000.
• On July 27, 2024, the company entered into a strategic investment agreement with a company wholly owned by one of its directors, issuing 140,749 shares of common stock valued at $745,000 and receiving $950,000 of service credits. As of December 31, 2025, $nil of related prepaid expenses were outstanding.
• On August 8, 2024, the company closed $209,000 in secured promissory notes with related parties, which were paid in full on the maturity date of August 23, 2024.
• On August 12, 2024, 59,264 shares of common stock were issued to related parties upon the vesting of restricted share units, recognizing $410,000 of share-based compensation expense.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity issuances and warrant exercises, as well as potential loss of investment due to the going concern uncertainty and increased net losses. The 'baby shelf' rule limits public capital raising, potentially forcing more dilutive private placements. The warrant exchange agreement in December 2025 resulted in a deemed dividend and further dilution.
• **Employees:** The company is highly dependent on its senior management and key personnel, with competition for skilled talent. Geopolitical conflicts in Israel could impact employees residing there, potentially leading to absences or operational disruptions. The company has 17 full-time employees as of the report date.
• **Customers (Clinicians & Patients):** The Evoke System aims to provide objective electrophysiological insights for brain health, potentially improving diagnostic and treatment planning. However, inadequate clinician training or misleading report results due to product variability could lead to dissatisfaction. Cybersecurity incidents could compromise patient data and trust.
• **Creditors:** The 'going concern' qualification raises concerns for potential and existing creditors regarding the company's ability to meet its obligations.
• **Regulatory Authorities:** The company is subject to rigorous regulation by the FDA and other authorities, with non-compliance potentially leading to sanctions, fines, or withdrawal of product clearances. Identified material weaknesses in internal controls require remediation to ensure compliance with SEC reporting requirements.

Next Steps

• Management will continue to pursue additional capital through equity or debt financings.
• Implement and complete remediation plans for identified material weaknesses in internal control over financial reporting throughout 2026.
• Continue disciplined operating expense management and realize integration synergies from the Evoke acquisition.
• Execute targeted commercial expansion to drive recurring subscription revenue across the combined product platform.
• File a registration statement on Form S-1 covering the resale of shares and warrant shares from the March 2026 Units Offering on or before April 15, 2026.
• Monitor and adapt to evolving regulatory guidance, including the FDA's approach to AI/ML-enabled medical devices.
• Invest greater resources to modify and enhance protective measures against cybersecurity risks.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by recurring losses, negative cash flows, and a significant accumulated deficit. While revenue growth is positive, it is overshadowed by increasing net losses and a substantial loss from derivative fair value. Identified material weaknesses in internal controls and the ongoing need for significant capital raises, coupled with the dilutive nature of recent financing activities (e.g., the warrant exchange at a significantly reduced exercise price), present considerable risks to shareholder value. Geopolitical risks related to operations in Israel further add to the uncertainty. A seasoned investor would likely view these factors as strong indicators of high risk and potential for further capital erosion.

Keywords

Neuroscience, Artificial Intelligence, EEG, ERP, Brain Health, Medical Devices, FDA Clearance, Cognitive Impairment, Mental Health Diagnostics, Biomarkers, Subscription Model, Evoke System, WaveDancer, SEC Filing, 10-K, Going Concern, Capital Raise, Warrants, Dilution, Cybersecurity, Corporate Governance